menu
    • menu
    [{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"LTS - Lohmann Therapie Systeme","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Livzon Pharmaceutical Group \/ LIVZON","highestDevelopmentStatusID":"4","companyTruncated":"Livzon Pharmaceutical Group \/ LIVZON"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Bright Peak Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"LZM009","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Onconic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Zastaprazan","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Livzon Pharmaceutical Group \/ Livzon Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Livzon Pharmaceutical Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Livzon Pharmaceutical Group

    Menu

    Livzon Pharmaceutical Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Livzon Pharmaceutical Group

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Livzon Pharmaceutical Group

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zastaprazan

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : Onconic Therapeutics

                            Deal Size : $127.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million

                            Details : Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan,...

                            Brand Name : JP 1366

                            Molecule Type : Small molecule

                            Upfront Cash : $15.0 million

                            March 14, 2023

                            Lead Product(s) : Zastaprazan

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : Onconic Therapeutics

                            Deal Size : $127.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Livzon Pharmaceutical Group

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Livzon Pharmaceutical Group

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LZM009

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bright Peak Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targete...

                            Details : Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs, including LZM009 on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the g...

                            Brand Name : LZM009

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 16, 2021

                            Lead Product(s) : LZM009

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bright Peak Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Livzon Pharmaceutical Group

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Livzon Pharmaceutical Group

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asenapine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : LTS - Lohmann Therapie Systeme

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LTS and LIVZON Enter into License and Collaboration Agreement to Develop and Commercialize Asenapine TTS

                            Details : LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and M...

                            Brand Name : Asenapine TTS

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 06, 2020

                            Lead Product(s) : Asenapine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : LTS - Lohmann Therapie Systeme

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth